Genetic research, conceptual image. DNA (deoxyribonucleic acid) autoradiogram in a petri dish.
Our Work

Latham & Watkins Advises Hg on Sale of MEDIFOX DAN

June 14, 2022
German-led team advised a leading software investor on the transaction.

Latham & Watkins LLP has advised Hg, a leading software and services investor, on the sale of MEDIFOX DAN, a leading provider of digital solutions for the German care and therapy sectors, to ResMed, a global leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions. The transaction is valued at approximately US$1 billion. 

Latham previously advised Hg on the acquisition of the MediFox Group in 2018 as well as several other transactions, including the acquisition of a majority stake in LucaNet AG and Fonds Finanz Maklerservice GmbH. 

The Latham team was led by Frankfurt partners Oliver Felsenstein and Maximilian Platzer, with associate Michele Maurice Stephan, Munich associate Corinna Freudenmacher, and Frankfurt counsel Christina Mann and legal analyst Franziska Ernst. Advice was also provid-ed on tax matters by Munich partner Stefan Süß; on IP matters by Frankfurt partner Susan Kempe-Müller, with associate Daniela Jaeger; on antitrust matters by Frankfurt partner Max Hauser, with associate Nicolas Jung; on regulatory matters by Frankfurt partner Axel Schie-mann, with associate Dominik Schöneberger; on litigation matters by Frankfurt partner Alena McCorkle, with Munich associate Martina Hölzer; on real estate matters by Frankfurt counsel Sven Nickel; on finance matters by Frankfurt partner Sibylle Münch, with associate Ralph Dräger; on data security matters by Frankfurt associates Wolf-Tassilo Böhm and Clemens Ganz; on employment matters by Munich partner Tobias Leder; and on compliance matters by Frankfurt counsel Dr. Stefan Bartz, with Munich associate Christoph von Laufenberg.

Endnotes